The soluble form of CD83 is present at elevated levels in a number of hematological malignancies.
Recombinant forms of soluble CD83 (sCD83) inhibit anti-tumor responses. In this analysis of circulating sCD83 levels we report that although >95% of acute myeloid leukemia (AML) and multiple myeloma (MM) patients have normal or only weakly elevated sCD83 levels, 20% of chronic lymphocytic leukemia (CLL) and 5/7 mantle cell lymphoma (MCL) patients have significantly elevated levels (>1 ng/ml). Isolated CLL cells both weakly expressed membrane CD83 (mCD83), and released sCD83 during in vitro culture. We conclude that malignant cells are a potential source of sCD83 and that it may have functional and/or prognostic significance in hematological malignancies, particularly CLL and MCL.
Hock
Barry D
BD
Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand. barry.hock@chmeds.ac.nz
Haring
Lisa F
LF
Steinkasserer
Alexander
A
Taylor
Karen G
KG
Patton
William N
WN
McKenzie
Judith L
JL
D000208:Acute Disease; D015703:Antigens, CD; D000951:Antigens, Neoplasm / Q000032:analysis* / Q000502:physiology; D019337:Hematologic Neoplasms / Q000097:blood*; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis* / Q000502:physiology; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood; D007951:Leukemia, Myeloid / Q000097:blood; D020522:Lymphoma, Mantle-Cell / Q000097:blood; D008562:Membrane Glycoproteins / Q000032:analysis* / Q000502:physiology; D009101:Multiple Myeloma / Q000097:blood; D014411:Neoplastic Stem Cells / Q000378:metabolism; D011379:Prognosis; D012995:Solubility; D000097802:CD83 Antigen
D015703:Antigens, CD; D000951:Antigens, Neoplasm; D007136:Immunoglobulins; D008562:Membrane Glycoproteins; D000097802:CD83 Antigen